HRAS
GTPase HRas
As of the edition of 20 October 2026, HRAS (GTPase HRas, UniProt P01112) has 2 drugs tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01112
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 254
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Immune system; Lungs and airways
- Registered trials of its drugs
- 5
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| ISIS-2503 | Went quiet | Phase 2 | none listed |
| Salirasib | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Concordia | Route A |
The other 0 companies at HRAS
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at HRAS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.